

## ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

### A021502 STUDY DOCUMENTS

#### RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR (ATOMIC)

*ClinicalTrials.gov Identifier: NCT02912559*

Study Activation Date: 09/12/2017

Study Closure Date: N/A

Patient Follow-up Termination Date: N/A

| DOCUMENT NAME                                                                                                                | EFFECTIVE DATE | ALLIANCE POSTING DATE |
|------------------------------------------------------------------------------------------------------------------------------|----------------|-----------------------|
| Activation (NCI Version 07/13/2017)<br>Memorandum Re: Requirements for NDA/Registration Trial                                | 09/12/2017     | 09/12/2017            |
| Update #01 (NCI Version 11/02/2017)<br>Memorandum Re: Delegation of Task Log Activation                                      |                | 12/15/2017            |
| Update #02 (NCI Version 05/08/2018)<br>Correlative Science Manual                                                            |                | 07/15/2018            |
| Update #03 (NCI Version 07/09/2018)<br>Memorandum Re: Delegation of Task Log Revision                                        |                | 08/01/2018            |
| Update #04 (NCI Version 09/21/2018)<br>Atezolizumab Action Letter<br>Broadcast Re: Action Letter: Immediate Action Required  |                | 10/05/2018            |
| Update #05 (NCI Version 02/05/2019)                                                                                          |                | 03/01/2019            |
| Update #06 (NCI Version 06/30/2020)                                                                                          |                | 08/01/2020            |
| Update #07 (NCI Version 10/29/2020)                                                                                          |                | 12/15/2020            |
| Update #08 (NCI Version 04/08/2021)                                                                                          |                | 05/01/2021            |
| Updated #09 (NCI Version 06/07/2021)<br>Atezolizumab Action Letter<br>Broadcast Re: Action Letter: Immediate Action Required |                | 06/23/2021            |
| Action Required<br>06/23/2021<br>Update #10 (NCI Version 10/15/2021)                                                         |                | 12/15/2021            |
| Update #11 (NCI Version 08/01/2022)                                                                                          |                | 09/01/2022            |
| Update #12 (NCI Version 08/25/2022)                                                                                          |                | 10/01/2022            |
| Update #13 (NCI Version 10/11/2022)                                                                                          |                | 12/01/2022            |
| Broadcast Re: Notice of Closure                                                                                              | 1/17/2023      | 02/01/2023            |
| Update #14 (NCI Version 05/23/2023)                                                                                          |                | 07/15/2023            |
| Update #15 (NCI Version 10/02/2023)<br>Atezolizumab Action Letter<br>Broadcast Re: Action Letter: Immediate Action Required  |                | 11/07/2023            |
| Update #16 (NCI Version 07/23/2024)                                                                                          |                | 09/03/2024            |
| Update #17 (NCI Version 01/06/2025)                                                                                          |                | 02/28/2025            |

